A multicentre, randomised, phase II trial of brigatinib consolidation versus observation or durvalumab in patients with unresectable stage III NSCLC and ALK-rearrangement, after definitive chemo-radiotherapy

BOUNCE: Brigatinib post definitive chemo-radiotherapy in patients with ALK-fusion non-small cell lung cancer

Trial Scheme

USZ STRIKE trial schema

 

 

Trial Information

Primary Endpoint:
Progression-free survival (PFS) according to RECIST v1.1
Secondary Endpoints:
Overall survival
CNS-relapse-free survival
Pattern of disease progression
Toxicity
Target Sample Size:
44 randomised patients (approximately 55 enrolled)
Protocol Release Date:
6 February 2024

Trial Organisation

Trial Chair:
Rafal Dziadziuszko, Gdansk, Poland
Trial Co-Chairs:
Sanjay Popat, London, United Kingdom
Sponsor:
ETOP IBCSG Partners Foundation
Coordinating Group:
ETOP IBCSG Partners Foundation
Participating Groups:
Spanish Lung Cancer Group (SLCG)
Participating Countries:  
France, Italy, Poland, Spain, United Kingdom
Registrations:
EU CT number: 2022-502467-38
clinicaltrials.gov: NCT05718297

Contact

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland
BOUNCE@etop.ibcsg.org

Log in to gain access to trial related material.

Log in